SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending after delivering exceptional financial results that paradoxically led to a notable stock decline, sparking community debate over market manipulation, "sell the news" reactions, and the sustainability of AI-driven demand across the broader tech sector.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy Enterprises is trending following a significant miss on recent financial results and disappointing guidance, which has sparked widespread investor anger and concerns over management's credibility. Despite community backlash and accusations of a pump-and-dump, a notable segment of investors views the sharp stock decline as an overreaction, presenting a potential 'buy the dip' opportunity in the long-term battery storage sector.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending after reporting strong quarterly financial results and significant share repurchases, yet community sentiment remains divided as the stock's price reaction is muted, fueling frustration over management's communication and ongoing speculation about the AUR200 pipeline and a potential buyout.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings (CELH) is trending after a strong Q4 earnings beat and optimistic statements from its CEO at the CAGNY conference regarding significant shelf space expansion for Celsius and Alani Nu. Community discussion reflects bullish enthusiasm for market share growth and potential PepsiCo buyout, yet also includes sharp criticism of the CEO and frustration over price volatility driven by profit-taking and broader market weakness.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is seeing a surge of interest after beating Q4 earnings with reported profitability and securing new Material Transfer Agreements, notably in oncology, fueling intense community discussions about a potential short squeeze as its convertible debt conversion price comes into play.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is surging following its strong Q4 revenue beat, raised 2026 guidance, and major contract awards like the $151 billion SHIELD defense program, fueling intense community debate between bullish investors anticipating a short squeeze and skeptics highlighting ongoing losses and high valuation.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as investors grapple with its recent financial results, which showed robust revenue despite significant losses, and the surprise announcement of CEO Doug Ingram's retirement, sparking divided community opinion on the company's valuation, pipeline prospects, and potential for a fresh start under new, potentially favorable FDA gene therapy guidance.

Red Robin Gourmet Burgers, Inc. develops, operates, and franchises full-service restaurants North America. It serves a variety of salads, soups, appetizers, other entrees, desserts, signature alcoholic and non-alcoholic beverages. The company was founded in September 1969 and is headquartered in Englewood, CO.

Red Robin Gourmet Burgers Inc

Red Robin Gourmet Burgers is experiencing a sharp ascent driven by a surprisingly strong earnings report, revealing significant operational improvements and debt reduction. Community discussion centers on the potential for a substantial short squeeze, given its low float and perceived undervaluation relative to comparable restaurant chains.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is a hot topic as it approaches its anticipated earnings report, with strong community discussion around its expanding agentic AI platform, new global innovation hub, and recent Sales Assist launch driving expectations for significant revenue growth. The potential for profitability and high short interest are further fueling investor attention, as many anticipate a notable market reaction to its results and forward guidance.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is at the center of investor discussion following its recent earnings, which highlighted a stable balance sheet and international growth amidst persistent challenges for its BetterHelp segment. This has polarized the community, with bulls seeing a deeply undervalued stock ready for a short squeeze, while bears remain skeptical of management's ability to drive sustained profitability in a competitive telehealth market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Corbus Pharmaceuticals Touts Catalyst-Rich 2026 With CRB-701 and CRB-913 Data Readouts Ahead

Corbus Pharmaceuticals (NASDAQ:CRBP) outlined a catalyst-rich 2026 at Oppenheimer's 36th Annual Healthcare Conference, with Chief Executive Officer Yuval Cohen highlighting upcoming mid-year and...

Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Rating Upgraded by Jefferies Financial Group

Jefferies Financial Group raised Corbus Pharmaceuticals to a "strong-buy" rating in a research note on Wednesday...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eleven research firms that are currently covering the firm...

Corbus Pharmaceuticals (NASDAQ:CRBP) COO Ian Hodgson Sells 2,415 Shares

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) COO Ian Hodgson sold 2,415 shares of the business's stock in a transaction that occurred on Tuesday, February 3rd. The stock was...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) have been given an average rating of "Moderate Buy" by the eleven analysts that are currently covering the company...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Consensus Rating of "Moderate Buy" from Brokerages

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has received an average recommendation of "Moderate Buy" from the eleven research firms that are presently covering the stock...

Corbus Pharmaceuticals (NASDAQ:CRBP) Shares Cross Below Fifty Day Moving Average - Should You Sell?

Corbus Pharmaceuticals (NASDAQ:CRBP) Share Price Passes Below Fifty Day Moving Average - Here's What Happened...

<ul class="summary-bullets"><li>CRB-913 is an oral small-molecule inverse agonist targeting the CB1 receptor, a known pathway for weight loss.</li><li>The study showed that participants reported reductions in food-related thoughts and cravings</li><li>Corbus has initiated a Phase 1b dose-finding study, CANYON-1, in people with obesity, with completion expected by summer 2026.</li></ul>Shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) surged 36% in premarket trading on Thursday after the company announced encouraging Phase 1a results for CRB-913, an oral CB1 inverse agonist targeting chronic obesity.At the time of writing, <a href="https://stocktwits.com/symbol/CRBP">CRBP</a> was among the top trending tickers on Stocktwits.<h2 class="st-heading-2">Results Of The Study</h2>Corbus Pharma said that the single-and multiple-ascending dose study showed that CRB-913 was safe and well-tolerated across all doses, with no serious treatment-emergent adverse events reported. Gastrointestinal issues were minimal, and daily neuropsychiatric assessments remained negative, indicating no signs of suicidality, depression, or anxiety.Participants reported reductions in food-related thoughts and cravings, highlighting early behavioral effects alongside weight reduction. Pharmacokinetic analysis confirmed that CRB-913 is suitable for once-daily oral dosing.Building on the early results, Corbus has initiated a Phase 1b dose-finding study, CANYON-1, in people with obesity, with completion expected by summer 2026. This next stage will further explore optimal dosing and continue evaluating safety, tolerability, and efficacy over a longer period.CRB-913 is an oral small-molecule inverse agonist targeting the CB1 receptor, a known pathway for weight loss. Unlike earlier drugs in this class that raised neuropsychiatric safety concerns, CRB-913 is designed for limited brain penetration to reduce those risks.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment flipped to ‘extremely’ bullish from ‘neutral’ a day earlier, accompanied by ‘extremely high’ message volumes.One user expressed optimism about the CANYON-1 study.<stembedurl>https://stocktwits.com/LuigiDurante/message/638840548</stembedurl>Year-to-date, the stock has declined nearly 15%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/msft-stock-appears-set-to-retest-200-dma-last-time-it-did-its-rebound-didn-t-endure/cLIxBZBREnI">MSFT Stock Appears Set To Retest 200-DMA – Last Time It Did, Its Rebound Didn’t Endure</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CRBP Stock Surged 36% Pre-Market – What Did Its Obesity Treatment Drug Study Reveal?

Corbus Pharmaceuticals said its Phase 1a study showed CRB-913 was safe and well-tolerated at all doses, with no serious adverse events reported.

Equity

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eleven ratings firms that are covering the stock, Marketbeat...

B. Riley Forecasts Lower Earnings for Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Equities researchers at B. Riley dropped their FY2025 earnings per share estimates for Corbus Pharmaceuticals in a report released...

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

Current Price	$8.14
Prev Close	$7.77
Open	$7.87
Dividend Yield	0.00%
50-Day Moving Average	$8.20
Beta	1.40
Avg. Volume	174,058.65
PE Ratio	-1.41

52-Week High	$20.56
52-Week Low	$4.64
Market Capitalization	$136.39M
EPS (Annual)	-$3.68
Price to Book	1.06
Revenue Per Employee	$0.00

CRBP
Corbus Pharmaceuticals Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRBP News

CRBPCorbus Pharmaceuticals Holdings Inc